PTPA and neoplasm: PP2A is now known to inhibit multitudinous growth and survival pathways, suggesting that the ability to activate PP2A in cancer may suppress the development of resistance, providing greater efficacy in reducing tumor burden when combined with specific inhibitors to pro-proliferative pathways [2].